Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences

被引:39
|
作者
Del Prete, Gregory Q. [1 ]
Lifson, Jeffrey D. [1 ]
Keele, Brandon F. [1 ]
机构
[1] Frederick Natl Lab Canc Res, AIDS & Canc Virus Program, Leidos Biomed Res Inc, Frederick, MD USA
基金
美国国家卫生研究院;
关键词
macaque; simian-human immunodeficiency virus; simian immunodeficiency virus; vaccine challenge; SIMIAN IMMUNODEFICIENCY VIRUS; RHESUS MACAQUES; MENSTRUAL-CYCLE; NEUTRALIZATION SENSITIVITY; DISEASE PROGRESSION; CYNOMOLGUS MACAQUES; PARTIAL PROTECTION; SIV CHALLENGES; INFECTION; SHIV;
D O I
10.1097/COH.0000000000000311
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewNonhuman primate (NHP) models of AIDS are powerful systems for evaluating HIV vaccine approaches in vivo. Authentic features of HIV-1 transmission, dissemination, target cell tropism, and pathogenesis, and aspects of anti-HIV-1 immune responses, can be recapitulated in NHPs provided the appropriate, specific model parameters are considered. Here, we discuss key model parameter options and their implications for HIV-1 vaccine evaluation.Recent findingsWith the availability of several different NHP host species/subspecies, different challenge viruses and challenge stock production methods, and various challenge routes and schemata, multiple NHP models of AIDS exist for HIV vaccine evaluation. The recent development of multiple new challenge viruses, including chimeric simian-human immunodeficiency viruses and simian immunodeficiency virus clones, improved characterization of challenge stocks and production methods, and increased insight into specific challenge parameters have resulted in an increase in the number of available models and a better understanding of the implications of specific study design choices.SummaryRecent progress and technical developments promise new insights into basic disease mechanisms and improved models for better preclinical evaluation of interventions to prevent HIV transmission.
引用
收藏
页码:546 / 554
页数:9
相关论文
共 50 条
  • [21] Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy
    Julg, Boris
    Stephenson, Kathryn E.
    Tomaka, Frank
    Walsh, Stephen R.
    Tan, C. Sabrina
    Lavreys, Ludo
    Sarnecki, Michal
    Ansel, Jessica L.
    Kanjilal, Diane G.
    Jaegle, Kate
    Speidel, Tessa
    Nkolola, Joseph P.
    Borducchi, Erica N.
    Braams, Esmee
    Pattacini, Laura
    Burgess, Eleanor
    Ilan, Shlomi
    Bartsch, Yannic
    Yanosick, Katherine E.
    Seaman, Michael S.
    Stieh, Daniel J.
    van Duijn, Janine
    Willems, Wouter
    Robb, Merlin L.
    Michael, Nelson L.
    Walker, Bruce D.
    Pau, Maria Grazia
    Schuitemaker, Hanneke
    Barouch, Dan H.
    NPJ VACCINES, 2024, 9 (01)
  • [22] Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies
    Seddiki, Nabila
    Levy, Yves
    CURRENT OPINION IN HIV AND AIDS, 2018, 13 (02) : 119 - 127
  • [23] Preventive strategies of perinatal HIV-1 transmission: an experience from Thailand
    Pancharoen, C
    Thisyakorn, U
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (02) : 179 - 182
  • [24] R Genetic Variation and HIV-1 Vaccine Efficacy: Context And Considerations
    Lassauniere, Ria
    Tiemessen, Caroline T.
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [25] Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial
    Gilbert, PB
    Peterson, ML
    Follmann, D
    Hudgens, MG
    Francis, DP
    Gurwith, M
    Heyward, WL
    Jobes, DV
    Popovic, V
    Self, SG
    Sinangil, F
    Burke, D
    Berman, PW
    JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (05): : 666 - 677
  • [26] The preventive phase I trial with the HIV-1 Tat-based vaccine
    Ensoli, Barbara
    Fiorelli, Valeria
    Ensoli, Fabrizio
    Lazzarin, Adriano
    Visintini, Raffaele
    Narciso, Pasquale
    Di Carlo, Aldo
    Tripiciano, Antonella
    Longo, Olimpia
    Bellino, Stefania
    Francavilla, Vittorio
    Paniccia, Giovanni
    Arancio, Angela
    Scoglio, Arianna
    Collacchi, Barbara
    Alvarez, Maria Jose Ruiz
    Tambussi, Giuseppe
    Din, Chiara Tassan
    Palamara, Guido
    Latini, Alessandra
    Antinori, Andrea
    D'Offizi, Gianpiero
    Giuliani, Massimo
    Giulianelli, Marina
    Carta, Maria
    Monini, Paolo
    Magnani, Mauro
    Garaci, Enrico
    VACCINE, 2009, 28 (02) : 371 - 378
  • [27] Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
    Hammer, Scott M.
    Sobieszczyk, Magdalena E.
    Janes, Holly
    Karuna, Shelly T.
    Mulligan, Mark J.
    Grove, Doug
    Koblin, Beryl A.
    Buchbinder, Susan P.
    Keefer, Michael C.
    Tomaras, Georgia D.
    Frahm, Nicole
    Hural, John
    Anude, Chuka
    Graham, Barney S.
    Enama, Mary E.
    Adams, Elizabeth
    DeJesus, Edwin
    Novak, Richard M.
    Frank, Ian
    Bentley, Carter
    Ramirez, Shelly
    Fu, Rong
    Koup, Richard A.
    Mascola, John R.
    Nabel, Gary J.
    Montefiori, David C.
    Kublin, James
    McElrath, M. Juliana
    Corey, Lawrence
    Gilbert, Peter B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (22): : 2083 - 2092
  • [28] Potential utility of GB virus type C as a preventive vaccine for HIV-1
    Bagasra, Omar
    Bagasra, Alexander U.
    Sheraz, Muhammad
    Pace, Donald Gene
    EXPERT REVIEW OF VACCINES, 2012, 11 (03) : 335 - 347
  • [29] Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial
    O'Connell, JM
    Hogg, RS
    Chan, K
    Strathdee, SA
    McLean, N
    Martindale, SL
    Willoughby, B
    Remis, R
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 (05) : 521 - 528
  • [30] Role of TLRs in HIV-1 Infection and Potential of TLR Agonists in HIV-1 Vaccine Development and Treatment Strategies
    Rozman, Marija
    Zidovec-Lepej, Snjezana
    Jambrosic, Karlo
    Babic, Maja
    Drmic Hofman, Irena
    PATHOGENS, 2023, 12 (01):